India’s diabetes and obesity treatment landscape changed dramatically in March 2026. Novo Nordisk’s core Indian patent for semaglutide expired on March 20, 2026 — within hours, a wave of Indian pharmaceutical companies launched their own versions at dramatically lower prices. Branded Ozempic costs ₹8,800–₹11,175 per month in India, while the cheapest generic is now available at ₹1,290 per month.
At the same time, Mounjaro became India’s top-selling drug by value within months of its launch — signalling a clear shift toward high-value chronic care treatments in India.
This article covers the clinical differences, latest India pricing, and trial evidence for the three most discussed GLP-1 medicines in India right now — Ozempic vs Mounjaro India — and Wegovy.
All prescribing decisions should be made by a qualified physician based on individual patient assessment.
What Are GLP-1 Receptor Agonists?
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of injectable medicines that mimic the GLP-1 hormone released naturally after meals. They work by stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon, slowing gastric emptying, and reducing appetite — resulting in improved blood sugar control and significant weight loss.
Three GLP-1 medicines are currently available and most discussed in India:
- Ozempic (Semaglutide) — approved for Type 2 diabetes
- Wegovy (Semaglutide 2.4mg) — approved for chronic weight management
- Mounjaro (Tirzepatide) — approved for Type 2 diabetes, demonstrated significant weight loss in clinical trials
The Key Difference — One Receptor vs Two
This is the most clinically important distinction between these medicines.
Ozempic and Wegovy contain Semaglutide — which targets only the GLP-1 receptor. Mounjaro contains Tirzepatide — which targets both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously.
This dual receptor action gives Mounjaro a meaningful clinical advantage in both glycemic control and weight reduction — as demonstrated across the SURPASS clinical trial programme. In the SURPASS-2 head-to-head trial published in the New England Journal of Medicine, Tirzepatide at 15mg achieved an HbA1c reduction of 2.46% compared to 1.86% for Semaglutide 1mg, and weight loss of 13.1kg compared to 6.2kg.
Clinical Comparison
| Feature | Ozempic | Wegovy | Mounjaro |
|---|---|---|---|
| Active Ingredient | Semaglutide | Semaglutide | Tirzepatide |
| Receptor Target | GLP-1 | GLP-1 | GLP-1 + GIP |
| Approved Indication | Type 2 Diabetes | Obesity/Weight Management | Type 2 Diabetes |
| HbA1c Reduction | Up to 1.8% | N/A | Up to 2.4% |
| Average Weight Loss | 4–6kg | 14.9–16% body weight | 12–22% body weight |
| Cardiovascular Evidence | Proven (SUSTAIN-6) | Proven (SELECT trial) | Ongoing (SURPASS-CVOT) |
| Dosing | Once weekly | Once weekly | Once weekly |
| India Availability | ✅ Available | ✅ Available | ✅ Available |
Latest India Pricing — April 2026
Ozempic (Branded): ₹8,800–₹11,175/month
Generic Semaglutide: From ₹1,290/month — CDSCO approved (Natco, Sun Pharma, Dr. Reddy’s, Zydus)
Wegovy: Approximately ₹14,000–₹16,400/month
Mounjaro: Approximately ₹12,000–₹18,000/month — no generic available
Clinical Profile Overview — Key Differences
Each medicine has a distinct clinical profile based on its approved indications and trial data:
Ozempic (Semaglutide) is approved for Type 2 diabetes management. The SUSTAIN-6 trial demonstrated significant cardiovascular outcomes benefit. Following the semaglutide patent expiry in March 2026, generic versions are now available in India at significantly lower cost points.
Wegovy (Semaglutide 2.4mg) is specifically approved for chronic weight management at a higher dose than Ozempic. The SELECT trial demonstrated cardiovascular outcomes benefit in patients with obesity and established cardiovascular disease — an important differentiator from a regulatory standpoint.
Mounjaro (Tirzepatide) is approved for Type 2 diabetes and targets both GLP-1 and GIP receptors — a dual mechanism that demonstrated greater HbA1c reduction and weight loss versus Semaglutide in the SURPASS-2 head-to-head trial. No generic Tirzepatide is currently available in India.
The appropriate medicine for any individual patient is a clinical decision based on their diagnosis, comorbidities, treatment history, and individual response — made exclusively by a qualified physician.
💊 Hospitals and clinics requiring a reliable supply of Ozempic, Mounjaro, or Wegovy can contact A.K. Pharma — a trusted GLP-1 medicine distributor in Delhi supplying genuine branded medicines to hospitals, diabetes clinics, and pharmacies across India. All three medicines are available — request a quote here.
Safety Information — For Healthcare Professionals
These medicines share common safety considerations that prescribers evaluate as part of clinical assessment:
- Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
- Not approved for Type 1 diabetes
- History of pancreatitis — evaluate carefully before prescribing
- Dose escalation protocols — gradual titration is standard clinical practice
- Renal function monitoring in patients with kidney disease
- Not recommended during pregnancy
Common side effects reported in clinical trials include nausea, vomiting, diarrhoea, and constipation — most pronounced during dose escalation phases.
Full prescribing information, contraindications, and safety data are available in each medicine’s approved prescribing information.
Generic Semaglutide in India — What the Data Shows
Following the March 2026 patent expiry, generic semaglutide products from CDSCO-approved manufacturers are now available in India. Regulatory approval requires demonstration of bioequivalence to the reference product — meaning the same active molecule at equivalent plasma concentrations.
Key factual points for prescribers:
- CDSCO-approved generics contain the same semaglutide molecule
- Delivery devices vary between brands — vials vs prefilled pens
- Dosing remains the same across brands
- Prescribers should verify the CDSCO approval status of any generic being considered
For patients on Mounjaro (Tirzepatide) — no generic is currently available given Tirzepatide’s patent status.
What This Means for Hospitals and Pharmacies
The GLP-1 agonist market has reached around ₹1,579 crore as of March 2026. Demand for all three medicines is accelerating and hospitals need reliable cold-chain-maintained stock.
For bulk supply of Ozempic, Wegovy, and Mounjaro — A.K. Pharma is a licensed GLP-1 medicine distributor in Delhi with cold chain storage and prompt supply across India. Contact us at 011 4172 6999 or WhatsApp +91 9810034827.